Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of amifampridine phosphate in congenital myasthenic syndromes
2018-002405-64Phase 3Terminated
- Sponsor
- Catalyst Pharmaceuticals
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amifampridine in congenital myasthenic syndrome (CMS), sponsored by Catalyst Pharmaceuticals. Primary endpoint: Safety and tolerability of amifampridine. Started Jun 2021; status: terminated.
02
Drugs
amifampridine
03
Conditions
congenital myasthenic syndrome (CMS)
Beyond the preview
Go deeper on 2018-002405-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002405-64.